Ikena Oncology, Inc.

NasdaqGM:IKNA Stock Report

Market Cap: US$66.1m

Ikena Oncology Valuation

Is IKNA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IKNA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IKNA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IKNA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IKNA?

Key metric: As IKNA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for IKNA. This is calculated by dividing IKNA's market cap by their current book value.
What is IKNA's PB Ratio?
PB Ratio0.5x
BookUS$125.93m
Market CapUS$66.11m

Price to Book Ratio vs Peers

How does IKNA's PB Ratio compare to its peers?

The above table shows the PB ratio for IKNA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average5.8x
PLRX Pliant Therapeutics
0.3x30.0%US$94.9m
VERU Veru
2.8x7.8%US$75.6m
ALTS ALT5 Sigma
18.1xn/aUS$66.5m
IBO Impact BioMedical
1.8xn/aUS$57.1m
IKNA Ikena Oncology
0.5x-9.0%US$66.1m

Price-To-Book vs Peers: IKNA is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (5.8x).

Price to Book Ratio vs Industry

How does IKNA's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
TLRY Tilray Brands
0.2x76.1%US$609.48m
CTXR Citius Pharmaceuticals
0.2x62.3%US$13.06m
PRPH ProPhase Labs
0.2x81.4%US$9.33m
RLMD Relmada Therapeutics
0.2x8.4%US$8.94m
IKNA 0.5xIndustry Avg. 1.3xNo. of Companies23PB012345+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: IKNA is good value based on its Price-To-Book Ratio (0.5x) compared to the US Pharmaceuticals industry average (1.3x).

Price to Book Ratio vs Fair Ratio

What is IKNA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IKNA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IKNA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IKNA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.37
US$3.00
+119.0%
33.3%US$4.00US$2.00n/a2
Mar ’26US$1.34
US$3.00
+123.9%
33.3%US$4.00US$2.00n/a2
Feb ’26US$1.48
US$3.00
+102.7%
33.3%US$4.00US$2.00n/a2
Jan ’26US$1.64
US$3.00
+82.9%
33.3%US$4.00US$2.00n/a2
Dec ’25US$1.73
US$3.00
+73.4%
33.3%US$4.00US$2.00n/a2
Nov ’25US$1.72
US$3.00
+74.4%
33.3%US$4.00US$2.00n/a2
Oct ’25US$1.70
US$3.00
+76.5%
33.3%US$4.00US$2.00n/a2
Sep ’25US$1.71
US$3.00
+75.4%
33.3%US$4.00US$2.00n/a2
Aug ’25US$1.68
US$3.00
+78.6%
33.3%US$4.00US$2.00n/a2
Jul ’25US$1.65
US$3.00
+81.8%
33.3%US$4.00US$2.00n/a2
Jun ’25US$1.77
US$3.00
+69.5%
33.3%US$4.00US$2.00n/a2
May ’25US$1.30
US$8.33
+541.0%
24.7%US$11.00US$6.00n/a3
Apr ’25US$1.39
US$8.33
+499.5%
24.7%US$11.00US$6.00n/a3
Mar ’25US$1.47
US$8.33
+466.9%
24.7%US$11.00US$6.00US$1.343
Feb ’25US$1.36
US$8.33
+512.7%
24.7%US$11.00US$6.00US$1.483
Jan ’25US$1.97
US$8.33
+323.0%
24.7%US$11.00US$6.00US$1.643
Dec ’24US$1.50
US$8.33
+455.6%
24.7%US$11.00US$6.00US$1.733
Nov ’24US$4.07
US$17.00
+317.7%
26.7%US$22.00US$11.00US$1.723
Oct ’24US$4.33
US$17.00
+292.6%
26.7%US$22.00US$11.00US$1.703
Sep ’24US$4.82
US$17.33
+259.6%
23.7%US$22.00US$12.00US$1.713
Aug ’24US$5.33
US$17.67
+231.5%
20.8%US$22.00US$13.00US$1.683
Jul ’24US$6.56
US$17.67
+169.3%
20.8%US$22.00US$13.00US$1.653
Jun ’24US$6.67
US$17.67
+164.9%
20.8%US$22.00US$13.00US$1.773
May ’24US$5.47
US$19.00
+247.3%
22.3%US$22.00US$13.00US$1.303
Apr ’24US$3.45
US$19.00
+450.7%
22.3%US$22.00US$13.00US$1.393
Mar ’24US$3.89
US$19.00
+388.4%
15.8%US$22.00US$16.00US$1.472
Analyst Price Target
Consensus Narrative from 2 Analysts
US$3.00
Fair Value
54.3% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 00:12
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ikena Oncology, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanCredit Suisse
Judah FrommerCredit Suisse
Robert BurnsH.C. Wainwright & Co.